- Home
- AMPL vs ARQT Comparison
AMPL vs ARQT Comparison
Compare AMPL & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPL
- ARQT
- Stock Information
- Founded
- AMPL 2012
- ARQT 2016
- Country
- AMPL United States
- ARQT United States
- Employees
- AMPL N/A
- ARQT N/A
- Industry
- AMPL EDP Services
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- AMPL Technology
- ARQT Health Care
- Exchange
- AMPL Nasdaq
- ARQT Nasdaq
- Market Cap
- AMPL 1.5B
- ARQT 1.7B
- IPO Year
- AMPL 2021
- ARQT 2020
- Fundamental
- Price
- AMPL $12.48
- ARQT $13.04
- Analyst Decision
- AMPL Buy
- ARQT Strong Buy
- Analyst Count
- AMPL 10
- ARQT 6
- Target Price
- AMPL $13.50
- ARQT $18.80
- AVG Volume (30 Days)
- AMPL 1.8M
- ARQT 2.2M
- Earning Date
- AMPL 05-07-2025
- ARQT 05-06-2025
- Dividend Yield
- AMPL N/A
- ARQT N/A
- EPS Growth
- AMPL N/A
- ARQT N/A
- EPS
- AMPL N/A
- ARQT N/A
- Revenue
- AMPL $306,601,000.00
- ARQT $212,819,000.00
- Revenue This Year
- AMPL $12.82
- ARQT $61.15
- Revenue Next Year
- AMPL $10.82
- ARQT $37.98
- P/E Ratio
- AMPL N/A
- ARQT N/A
- Revenue Growth
- AMPL 8.56
- ARQT 100.03
- 52 Week Low
- AMPL $7.37
- ARQT $6.99
- 52 Week High
- AMPL $14.88
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- AMPL 61.97
- ARQT 40.51
- Support Level
- AMPL $11.78
- ARQT $13.27
- Resistance Level
- AMPL $12.79
- ARQT $14.30
- Average True Range (ATR)
- AMPL 0.53
- ARQT 0.71
- MACD
- AMPL 0.04
- ARQT -0.07
- Stochastic Oscillator
- AMPL 73.36
- ARQT 10.94
About AMPL Amplitude Inc.
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue primarily through selling subscriptions to the platform. The company derives a majority of its revenue from the United States.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.